Add thelocalreport.in As A Trusted Source
New one drug combination has been found to expand lifespan in weak, elderly, male rats By a “remarkable 73 percent”, according to a new study that sheds more light on the anti-gender bias.Ageing treatment
researcher A dual-drug approach targeting two known biological pathways was tested changes with age,
he tested oxytocinwhich is known to aid tissue repair, as well as another drug called OT+A5i, which blocks a key pathway involved in regulating cell growth, differentiation and death.
The key pathway known as TGF-beta becomes overactive with age, contributing to chronic inflammation and tissue damage.
Researchers tested the drug combo on weakened mice at 25 months of age – the equivalent of about 75 human years.
They found that male mice that received the therapy lived 70 percent longer than untreated mice and saw significant improvements in physical endurance, agility and memory.
According to the research published in the journal, scientists found that male mice treated with the drug combination were about three times less likely to die at any time than untreated male mice. Aging-US.
“Treatment of old debilitated male mice with OT+A5i resulted in a remarkable 73 percent life extension compared to that time and a 14 percent increase in overall mean lifespan,” the researchers wrote.
He added, “In addition, these animals have significantly increased health span with improvements in physical performance, endurance, short-term memory, and resilience to mortality.”
By comparison, previous studies of the popular anti-aging drug rampamycin showed that when measured from the beginning of therapy, the survival rate of mice increased by 9 to 15 percent, the researchers say.
“Compared to other established lifespan-extending interventions, oxytocin+A5i demonstrates unique results, such that the introduction of this therapy in old and debilitated male rats resulted in a significant (by more than 70 percent) increase in life expectancy, and a substantial reduction in mortality risk,” they wrote.
The latest study also found that oxytocin + A5i treatment reduced the levels of certain circulating blood proteins, which are key markers of aging, returning their levels to more youthful levels.
However, after four months of continuous treatment, only male mice showed sustained improvements in these protein levels.
The researchers found that female mice did not experience significant benefits in lifespan or health span.
The findings highlight the importance of better understanding gender-specific biology when developing aging treatments.
“These findings establish the significant health-span extension potential of OT+A5i and emphasize aging and differences in response to longevity treatment between the sexes,” the scientists wrote.
Researchers hope this discovery could provide a new model for studying and designing longevity treatments.